Bookmark and Share
BioAssay: AID 588346

qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a: Hit Confirmation in b-rIgG Counterscreen

Methylated lysines, on the N-terminal tails of histone proteins serve as epigenetic markers to recruit factors that can then modify local chromatin structure to lead to functional consequences. G9a and other members of the SUV39 family of the SET domain-containing superfamily of histone lysine methyltransferases (HMT) have been identified to specifically methylate Lys9 of histone H3 (H3K9). G9a more ..
_
   
 Tested Compounds
 Tested Compounds
All(93)
 
 
Active(2)
 
 
Inactive(48)
 
 
Inconclusive(43)
 
 
 Tested Substances
 Tested Substances
All(94)
 
 
Active(2)
 
 
Inactive(48)
 
 
Inconclusive(44)
 
 
AID: 588346
Data Source: NCGC (G9A201)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-09-07

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 2
Related Experiments
AIDNameTypeComment
504404qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a: SummarySummarydepositor-specified cross reference: Summary AID of project
504332qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9aConfirmatorysame project related to Summary assay
588344qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a: Hit ConfirmationConfirmatorysame project related to Summary assay
Description:
Methylated lysines, on the N-terminal tails of histone proteins serve as epigenetic markers to recruit factors that can then modify local chromatin structure to lead to functional consequences. G9a and other members of the SUV39 family of the SET domain-containing superfamily of histone lysine methyltransferases (HMT) have been identified to specifically methylate Lys9 of histone H3 (H3K9). G9a catalyzes the mono- and di-methylation of H3K9 in mammalian euchromatic regions, where the resulting H3K9me2 is indicative of transcriptional repression. Hence, G9a has been recognized as a potential drug target for several human diseases, including cancer. The inhibition of G9a will result in transcriptional activation and work synergistically with DNA methyltransferase and histone deacetylase inhibitors, to kill cancer cells.

This qHTS assay for identification of G9a inhibitors is a chemiluminescence based AlphaScreen (PerkinElmer) [1]. Methylation of biotinylated-histone peptide is measured through specific antibody-based detection, in conjunction with streptavidin-coated donor and anti-IgG antibody-coated acceptor beads. The method is particularly well suited for detection of inhibitors acting by the desired histone peptide competitive mechanism and is applicable to testing other HMTs.

Although AlphaScreen has significant advantages with its utility in a variety of epigenetic target assays, the primary screening data provided in this deposition should be used with caution due to the prevalence of screening artifacts [2]. Because an AlphaScreen counterscreen is highly recommended to be run against any putative actives to eliminate non specific artifacts, this assay was used as a counterscreen.

[1] Quinn et al. A chemiluminescence-based method for identification of histone lysine methyltransferase inhibitors. Mol Biosyst 6(5): 782-8. 2010. PMID: 20567762

[2] Baell,Holloway. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 53(7):2719-40. 2010. PMID: 20131845

NIH Chemical Genomics Center [NCGC]
NIH Molecular Libraries Probe Production Network [MLPCN]

MLPCN Grant: MH084681-02
Assay Submitter (PI): Structural Genomic Consortium - Toronto, Peter Brown
Protocol
Biotinylated rabbit-IgG (b-rIgG) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was added to 1,536-well plates in a 3 uL dispense. Compounds were added in a 23 nL pin-transfer step, and plates were incubated at room temperature for 15 min. Streptavidin-coated donor and anti-rIgG acceptor AlphaScreen beads were added (1 uL) for final concentrations of 20 ug/mL each bead and 1 nM b-rIgG, and plates read on the Envision after a 15 min incubation at room temperature in the dark.
Comment
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Categorized Comment - additional comments and annotations
From ChEMBL:
Assay Type: Functional
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1PhenotypeIndicates type of activity observed: inhibitor, activator, fluorescent, cytotoxic, inactive, or inconclusive.String
2Potency*Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.FloatμM
3EfficacyMaximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.Float%
4Analysis CommentAnnotation/notes on a particular compound's data or its analysis.String
5Curve_DescriptionA description of dose-response curve quality. A complete curve has two observed asymptotes; a partial curve may not have attained its second asymptote at the highest concentration tested. High efficacy curves exhibit efficacy greater than 80% of control. Partial efficacies are statistically significant, but below 80% of control.String
6Fit_LogAC50The logarithm of the AC50 from a fit of the data to the Hill equation (calculated based on Molar Units).Float
7Fit_HillSlopeThe Hill slope from a fit of the data to the Hill equation.Float
8Fit_R2R^2 fit value of the curve. Closer to 1.0 equates to better Hill equation fit.Float
9Fit_InfiniteActivityThe asymptotic efficacy from a fit of the data to the Hill equation.Float%
10Fit_ZeroActivityEfficacy at zero concentration of compound from a fit of the data to the Hill equation.Float%
11Fit_CurveClassNumerical encoding of curve description for the fitted Hill equation.Float
12Excluded_PointsWhich dose-response titration points were excluded from analysis based on outlier analysis. Each number represents whether a titration point was (1) or was not (0) excluded, for the titration series going from smallest to highest compound concentrations.String
13Max_ResponseMaximum activity observed for compound (usually at highest concentration tested).Float%
14Activity at 0.0000645146 uM (6.45146e-05μM**)% Activity at given concentration.Float%
15Activity at 0.0001935439 uM (0.000193544μM**)% Activity at given concentration.Float%
16Activity at 0.0003225731 uM (0.000322573μM**)% Activity at given concentration.Float%
17Activity at 0.0005806316 uM (0.000580632μM**)% Activity at given concentration.Float%
18Activity at 0.0009424649 uM (0.000942465μM**)% Activity at given concentration.Float%
19Activity at 0.00189 uM (0.00188512μM**)% Activity at given concentration.Float%
20Activity at 0.00290 uM (0.00290316μM**)% Activity at given concentration.Float%
21Activity at 0.00566 uM (0.00565537μM**)% Activity at given concentration.Float%
22Activity at 0.00871 uM (0.00870947μM**)% Activity at given concentration.Float%
23Activity at 0.017 uM (0.0169661μM**)% Activity at given concentration.Float%
24Activity at 0.026 uM (0.0261482μM**)% Activity at given concentration.Float%
25Activity at 0.052 uM (0.0518436μM**)% Activity at given concentration.Float%
26Activity at 0.079 uM (0.0790173μM**)% Activity at given concentration.Float%
27Activity at 0.153 uM (0.152695μM**)% Activity at given concentration.Float%
28Activity at 0.235 uM (0.234877μM**)% Activity at given concentration.Float%
29Activity at 0.456 uM (0.45573μM**)% Activity at given concentration.Float%
30Activity at 0.709 uM (0.709254μM**)% Activity at given concentration.Float%
31Activity at 1.448 uM (1.44816μM**)% Activity at given concentration.Float%
32Activity at 2.142 uM (2.14172μM**)% Activity at given concentration.Float%
33Activity at 6.120 uM (6.12011μM**)% Activity at given concentration.Float%
34Activity at 9.035 uM (9.03508μM**)% Activity at given concentration.Float%
35Activity at 18.45 uM (18.4477μM**)% Activity at given concentration.Float%
36Activity at 28.57 uM (28.5714μM**)% Activity at given concentration.Float%
37Activity at 55.68 uM (55.6829μM**)% Activity at given concentration.Float%
38Activity at 114.3 uM (114.286μM**)% Activity at given concentration.Float%
39Compound QCNCGC designation for data stage: 'qHTS', 'qHTS Verification', 'Secondary Profiling'String

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: MH084681

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: